FDA approves Roche Polivy combination therapy to treat relapsed patients with diffuse large B-cell lymphoma

recently, the United StatesThe FDA(http://approved Roche Polivy (formerly known as polatuzumab) in combination with rituxima and chemotherapy benzodiazepines for use in patients with diffuse large B-cell lymphoma who had previously failed or relapsed in at least two previous treatmentsAt the moment, Roche's lucrative cancer-heavydrug(http://increasingly under attack from a growing number of bio-
pharmaceutical(http://, but now thecompany(http://Polivy has received FDA approval for treatment for diffuse large B-cell lymphoma, which appears to have become the only effective treatment for this type of patientPreviously, the FDA approved the Polivy portfolio priority review and breakthrough treatment designationPolivy's activetrial(http:// in Phase 1b/2resulted in it giving it a regulatory green lightresults showed that the combination was more effective than the usual treatment therapy for benzoystinandin and Rituxan pairingsIn this trial, 40 percent of patients used the Polivy combination to achieve a full efficacy response, compared with only 18 percent in the benzoystin and Rituxan groupsat the end of the treatment process, 45 percent of patients in the Polivy combination had an objective response, compared with only 18 percent in the benzostin and Rituxan groups